Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) has been given a consensus recommendation of “Hold” by the fourteen research firms that are presently covering the company, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $108.1111.
A number of analysts recently weighed in on the company. TD Cowen downgraded Lantheus from a “buy” rating to a “hold” rating and dropped their target price for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Mizuho cut their price objective on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Wednesday, July 29th. Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Brookline Capital Markets downgraded shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Truist Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating and cut their price target for the company from $125.00 to $102.50 in a research report on Monday, August 3rd.
View Our Latest Research Report on LNTH
Lantheus Stock Down 0.0%
Lantheus (NASDAQ:LNTH – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.25. The firm had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.57 EPS. Equities research analysts expect that Lantheus will post 4.5 earnings per share for the current fiscal year.
Institutional Trading of Lantheus
Several hedge funds and other institutional investors have recently bought and sold shares of LNTH. EverSource Wealth Advisors LLC boosted its stake in shares of Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 698 shares during the period. First Trust Advisors LP increased its stake in shares of Lantheus by 37.4% in the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock worth $5,714,000 after buying an additional 19,008 shares during the period. Baird Financial Group Inc. increased its stake in shares of Lantheus by 22.6% in the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock worth $222,000 after buying an additional 500 shares during the period. Daiwa Securities Group Inc. raised its holdings in Lantheus by 88.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock valued at $278,000 after buying an additional 1,591 shares during the last quarter. Finally, Osterweis Capital Management Inc. purchased a new stake in Lantheus during the 2nd quarter valued at $36,000. Institutional investors own 99.06% of the company’s stock.
About Lantheus
Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.
The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.
See Also
- Five stocks we like better than Lantheus
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
